Drugs / ARI-0001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05641428 | Oct 2022 → Dec 2025 overdue | diffuse large B-cell lymphoma | University Medical Center Groningen | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07412405 | Sep 2026 → Sep 2028 expected | B-cell adult acute lymphocytic leukemia, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma +1 | GUSTAVO SALGUERO | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARI-0001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05641428 ↗ |
| Modality | Cell therapy | “The production of ARI-0001 cells consists of the genetic modification of autologous T cells through lentiviral transduction of a chimeric antigen receptor (CAR)” NCT07412405 ↗ |
| Target | CD19 | “a chimeric antigen receptor (CAR) targeting the CD19 surface antigen” NCT07412405 ↗ |